New eczema drug enters first human safety tests
NCT ID NCT07453602
Summary
This is the first study in humans testing a new drug called ARQ-234 for moderate to severe eczema (atopic dermatitis). Researchers will give single and multiple doses to healthy volunteers and people with eczema to check if it's safe, how the body processes it, and if it shows early signs of helping reduce eczema symptoms. The study will enroll about 125 adults and is focused primarily on establishing safety before testing effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Site 101
RECRUITINGFair Lawn, New Jersey, 07410, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.